Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 50.38 | 0.11 | — | 0.12 | — | 0.10 | — | 0.44 | 0.12 | 0.11 | — | 0.11 | — | 0.14 | 0.43 | 0.10 | 0.16 | 0.10 | — | 0.19 | 0.28 |
| — | +15.0% | — | -73.1% | — | -8.5% | — | +312.0% | — | -21.5% | — | +4.0% | — | +32.3% | — | -44.7% | -41.7% | +9.4% | — | +19.7% | -91.9% | |
| P/S Ratio | 2.14 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| — | -5.0% | +16.3% | +12.3% | +6.6% | +30.3% | +7.7% | -9.9% | -16.1% | -26.7% | -25.5% | -8.9% | +14.7% | +3.5% | +7.6% | -6.2% | -34.0% | -18.5% | -30.7% | -30.5% | -13.9% | |
| P/B Ratio | 1.32 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -4.8% | +9.3% | +15.5% | -2.1% | +35.6% | +13.2% | -15.7% | -3.4% | -25.8% | -28.4% | -15.4% | +13.4% | +2.8% | +5.4% | -1.5% | -37.9% | -30.8% | -28.5% | -34.9% | -19.2% | |
| P/FCF | 12.67 | 0.17 | — | 0.08 | 0.04 | 0.09 | 0.07 | 0.03 | 0.05 | 0.09 | 0.05 | 0.16 | 0.09 | — | — | 0.04 | 0.06 | — | 0.03 | 0.04 | 0.07 |
| — | +99.2% | — | +158.1% | -28.2% | -4.0% | +45.7% | -80.3% | -47.4% | — | — | +336.3% | +67.1% | — | — | +4.2% | -17.6% | — | -29.9% | -56.4% | +0.1% | |
| EV / EBITDA | 10.88 | 3.63 | 5.09 | 2.74 | 3.66 | 2.87 | 9.09 | 4.32 | 2.81 | 3.29 | 11.89 | 3.79 | 5.77 | 3.29 | 3.90 | 2.82 | 3.65 | 3.24 | 5.88 | 3.48 | 3.86 |
| — | +26.3% | -44.0% | -36.6% | +30.0% | -12.7% | -23.5% | +14.1% | -51.3% | -0.1% | +204.7% | +34.3% | +58.1% | +1.7% | -33.6% | -19.1% | -5.3% | +33.3% | +82.9% | -6.0% | -33.3% | |
| EV / EBIT | 25.39 | 5.00 | — | 4.05 | 9.01 | 4.08 | — | 181.26 | 5.64 | 6.01 | 7.10 | 15.80 | — | 5.76 | 25.59 | 4.88 | 8.41 | 4.74 | — | 7.72 | 9.09 |
| — | +22.6% | — | -97.8% | +59.7% | -32.1% | — | +1047.4% | — | +4.4% | -72.3% | +223.5% | — | +21.4% | — | -36.8% | -7.5% | +46.6% | — | +5.5% | -59.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.1% | 66.7% | 48.8% | 54.4% | 65.8% | 65.2% | 63.7% | 63.6% | 66.5% | 68.0% | 63.1% | 65.8% | 67.1% | 69.7% | 67.6% | 69.4% | 69.5% | 69.9% | 64.7% | 68.8% | 67.4% |
| — | +2.2% | -23.4% | -14.4% | -0.9% | -4.0% | +0.9% | -3.5% | -0.9% | -2.4% | -6.6% | -5.1% | -3.5% | -0.3% | +4.5% | +0.8% | +3.2% | -6.3% | -3.6% | -1.4% | -1.5% | |
| Operating Margin | 12.0% | 16.5% | 4.3% | 16.0% | 6.2% | 16.7% | -7.1% | 5.9% | 15.7% | 13.8% | -1.0% | 9.4% | -4.7% | 15.9% | 9.3% | 13.4% | 10.4% | 15.5% | -0.2% | 12.9% | 11.5% |
| — | -1.0% | +160.0% | +173.4% | -60.4% | +21.1% | -642.0% | -38.0% | +431.2% | -13.5% | -110.3% | -29.6% | -145.4% | +2.9% | +5095.8% | +3.7% | -9.6% | -40.9% | -100.9% | -24.5% | +88.4% | |
| Net Margin | 4.3% | 9.3% | -2.2% | 8.7% | -1.1% | 11.2% | -9.8% | 2.1% | 7.8% | 7.9% | -0.3% | 9.5% | -4.6% | 8.4% | 3.3% | 10.9% | 6.2% | 10.8% | -1.3% | 6.4% | 5.4% |
| — | -17.3% | +77.3% | +318.3% | -113.6% | +42.4% | -3311.1% | -78.1% | +270.0% | -6.6% | -108.8% | -12.4% | -174.7% | -21.8% | +350.4% | +69.5% | +13.2% | -25.5% | -105.1% | -41.9% | +963.3% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.8% | 1.5% | -0.3% | 1.4% | -0.2% | 1.8% | -1.4% | 0.3% | 1.3% | 1.3% | -0.0% | 1.5% | -0.7% | 1.3% | 0.5% | 1.8% | 0.9% | 1.8% | -0.2% | 1.1% | 0.9% |
| — | -18.2% | +77.7% | +330.3% | -113.5% | +42.5% | -3236.0% | -78.3% | +282.2% | -6.2% | -108.7% | -17.2% | -172.4% | -23.1% | +341.0% | +70.5% | +8.9% | -33.8% | -105.1% | -45.4% | +908.5% | |
| ROA | 1.4% | 0.7% | -0.2% | 0.7% | -0.1% | 0.9% | -0.7% | 0.2% | 0.6% | 0.6% | -0.0% | 0.7% | -0.3% | 0.6% | 0.2% | 0.8% | 0.4% | 0.8% | -0.1% | 0.5% | 0.4% |
| — | -17.5% | +77.2% | +340.4% | -113.9% | +44.7% | -3313.1% | -77.9% | +284.6% | -2.3% | -109.1% | -14.3% | -175.1% | -19.3% | +358.2% | +85.4% | +18.2% | -28.4% | -105.6% | -38.8% | +1028.5% | |
| ROIC | 3.7% | 1.3% | 0.3% | 1.3% | 0.5% | 1.3% | -0.5% | 0.4% | 1.2% | 1.0% | -0.1% | 0.7% | -0.3% | 1.2% | 0.7% | 1.1% | 0.7% | 1.2% | -0.0% | 1.0% | 0.8% |
| — | -0.2% | +160.5% | +189.0% | -60.1% | +21.3% | -642.2% | -37.1% | +460.7% | -11.9% | -110.0% | -35.3% | -143.4% | +1.1% | +5061.2% | +10.6% | -8.1% | -44.5% | -101.0% | -19.5% | +103.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.63 | 0.65 | 0.63 | 0.63 | 0.65 | 0.66 | 0.65 | 0.65 | 0.73 | 0.70 | 0.67 | 0.69 | 0.66 | 0.69 | 0.69 | 0.69 | 0.71 | 0.73 | 0.76 | 0.82 | 0.79 |
| — | -0.4% | -3.5% | -2.7% | -10.7% | -6.6% | -2.2% | -5.7% | +10.3% | +2.5% | -3.4% | -0.3% | -6.2% | -5.9% | -9.8% | -15.0% | -11.2% | -13.4% | -14.6% | -20.2% | -24.4% | |
| Debt / EBITDA | 3.67 | 15.82 | 22.87 | 12.51 | 16.94 | 12.30 | 39.31 | 19.06 | 13.41 | 15.29 | 52.01 | 15.97 | 24.51 | 13.96 | 17.53 | 13.24 | 17.40 | 14.90 | 28.84 | 16.51 | 17.77 |
| — | +28.5% | -41.8% | -34.4% | +26.4% | -19.5% | -24.4% | +19.3% | -45.3% | +9.5% | +196.7% | +20.7% | +40.9% | -6.3% | -39.2% | -19.8% | -2.1% | +32.4% | +80.4% | -1.7% | -32.2% | |
| Current Ratio | 1.27 | 1.14 | 1.27 | 1.19 | 1.36 | 1.16 | 1.01 | 1.31 | 1.28 | 1.26 | 1.11 | 1.06 | 1.04 | 0.99 | 0.97 | 1.16 | 1.15 | 1.18 | 1.21 | 1.37 | 1.28 |
| — | -1.6% | +26.5% | -9.1% | +6.7% | -8.1% | -9.1% | +23.4% | +23.0% | +27.6% | +14.5% | -8.3% | -9.4% | -16.0% | -20.1% | -15.3% | -10.3% | -18.9% | -21.0% | -5.5% | -15.3% | |
| Quick Ratio | 0.70 | 0.62 | 0.70 | 0.65 | 0.76 | 0.59 | 0.52 | 0.72 | 0.77 | 0.74 | 0.58 | 0.55 | 0.55 | 0.56 | 0.57 | 0.75 | 0.75 | 0.75 | 0.81 | 0.92 | 0.87 |
| — | +5.0% | +34.0% | -8.9% | -2.1% | -21.0% | -10.8% | +30.3% | +40.3% | +33.8% | +2.5% | -26.0% | -26.4% | -25.8% | -29.9% | -19.0% | -14.1% | -24.7% | -26.6% | -11.4% | -19.1% | |
| Interest Coverage | 1.73 | 3.55 | -0.20 | 2.08 | 1.34 | 2.41 | -25.74 | 29.19 | 2.74 | 3.29 | 490.96 | 1.05 | -94.57 | 3.27 | 117.56 | 2.34 | 2.20 | 3.80 | -0.86 | 2.55 | 2.55 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TAK stock.
Takeda Pharmaceutical Company Limited's current P/E is 50.4x. The average P/E over the last 2 quarters is 0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Takeda Pharmaceutical Company Limited's current operating margin is 12.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Takeda Pharmaceutical Company Limited's business trajectory between earnings reports.